Efficacy and safety of transcatheter arterial chemoembolization using combination of epirubicin and miriplatin for hepatocellular carcinoma -Prospective comparative study with transcatheter arterial chemoembolization using epirubicin- - TACE using combination of epirubicin&miriplatin for HCC - Prospective comparative study with TACE using epirubicin

Kansai Medical University0 个研究点目标入组 60 人开始时间: 2012年10月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) History of previous treatment by platinum drugs. 2) Extrahepatic metastasis. 3) Advanced vascular or biliary invasion (Vp3, Vp4, Vv3, B3, B4). 4) Severe arterio-portal shunt or arterio-venous shunt. 5) Difficult to perform transcatheter arterial chemotherapy. 6) History of the biliary tract reconstruction or treatment. 7) Patients with following severe complicating disease(except chronic hepatitis and liver cirrhosis). 1. Heart failure 2. Renal failure(GFR:<15mL/min/1.73m2) 3. Active infections(except viral hepatitis) 4. Active gastrointestinal bleeding 5. Active duplicative cancer 6. Hepatic encephalopathy or severe mental illness 8) Fever>=38.0 degrees Celsius. 9) History of hypersensitivity to iodine-containing contrast agent, gadolinium-containing contrast agent, epirubicin and platinum-containing drug. 10) Patients who are pregnant, lactating, suspected to be pregnant, or wish to become pregnant. 11) Patients who are concluded to be inappropriate to undergo TACE by angiography. 12) Patients who are concluded to be inappropriate to participate in this study by their physicians.

发起方